Comorbidity in inflammatory diseases of joints and spine (clinical aspects)

The article presents an analysis of the current view of comorbidity problem in rheumatology from the perspective of inflammatory disorders of the joints and spine combination with the most common diseases of the internal organs and endocrine system. The data gained from recent sources regarding the frequency and structure of concomitant disorders in patients with rheumatoid arthritis (RA) and spondylarthritis (ankylosing spondylitis [AS] and psoriatic arthritis [PsA]) are presented. It has been shown that the most common comorbidity in patients with RA, AS, PsA are diseases of the gastrointestinal tract and cardiovascular diseases. The authors present the results of their own research on the study of comorbidity in RA, AS and PsA, which are consistent with modern literature data. It is noted that there are specific disease-associated factors, as well as the negative effect of anti-inflammatory drugs in the development and manifestation of comorbid pathology.

[1]  I. Bruce,et al.  EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome , 2022, Annals of the Rheumatic Diseases.

[2]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[3]  E. Nasonov,et al.  The prevalence of comorbid and concomitant diseases in psoriatic arthritis patients, data from Russian register , 2021, Rheumatology Science and Practice.

[4]  E. Nasonov,et al.  Factors of Progression and Occurrence of Atherosclerosis in Rheumatoid Arthritis. , 2021, Kardiologiia.

[5]  J. Primdahl,et al.  Response to: ‘Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al’ by Wei et al , 2020, Annals of the Rheumatic Diseases.

[6]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[7]  E. Kalinina,et al.  FRI0025 DOES COMORBIDITY IMPACT ON THE ACTIVITY AND MANAGEMENT OF RHEUMATOID ARTHRITIS? , 2019, Poster Presentations.

[8]  T. E. Morozova,et al.  Comorbidities in clinical practice. Algorithms for diagnostics and treatment , 2019, Cardiovascular Therapy and Prevention.

[9]  L. Jacobsson,et al.  Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study , 2019, Arthritis Research & Therapy.

[10]  Xue Song,et al.  Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data. , 2019, Journal of managed care & specialty pharmacy.

[11]  P. Ambrosino,et al.  Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients , 2018, Reviews on recent clinical trials.

[12]  M. A. Osadchuk,et al.  AB0328 Cardiovascular risk evaluation in long standing rheumatoid arthritis: real clinical data , 2018 .

[13]  T. Mikuls,et al.  State of the Art Review: Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications , 2018 .

[14]  L. Punzi,et al.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study , 2018, Clinical Rheumatology.

[15]  Y. Narisawa,et al.  Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients , 2017, The Journal of dermatology.

[16]  R. Elosua,et al.  Association between chronic immune-mediated inflammatory diseases and cardiovascular risk , 2017, Heart.

[17]  Андрей Евгеньевич Каратеев,et al.  Коморбидная патология пищеварительной системы у больных ревматическими заболеваниями: не только НПВП-гастропатия , 2016, RSP 2016.

[18]  G. Kitas,et al.  Cardiovascular comorbidity in rheumatic diseases , 2015, Nature Reviews Rheumatology.

[19]  S. Mori,et al.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. , 2015, World journal of gastroenterology.

[20]  E. Nasonov,et al.  [Rheumatic diseases and multimorbidity]. , 2015, Terapevticheskii arkhiv.

[21]  Array А. Галушко,et al.  ПОРАЖЕНИЕ КИШЕЧНИКА У БОЛЬНЫХ СПОНДИЛОАРТРИТАМИ , 2015 .

[22]  Наталья Владимировна Чичасова,et al.  КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике» , 2015 .

[23]  G. Kitas,et al.  Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms , 2015, Annals of the rheumatic diseases.

[24]  G. Kitas,et al.  Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. , 2014, Atherosclerosis.

[25]  Е. А. Галушко,et al.  Концепция мультиморбидности в ревматологической практике , 2014, RSP 2014.

[26]  P. Muntner,et al.  The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[27]  M. González-Gay,et al.  Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis , 2014, The Journal of Rheumatology.

[28]  Jonathan Kay,et al.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) , 2013, Annals of the rheumatic diseases.

[29]  C. Torp-Pedersen,et al.  Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study , 2013, Annals of the rheumatic diseases.

[30]  F. Wolfe,et al.  Effect of body mass index on mortality and clinical status in rheumatoid arthritis , 2012, Arthritis care & research.

[31]  G. Kitas,et al.  B-type natriuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant? , 2012, Autoimmunity reviews.

[32]  D. Vassilopoulos,et al.  Management of rheumatic disease with comorbid HBV or HCV infection , 2012, Nature Reviews Rheumatology.

[33]  G. Kitas,et al.  Apolipoprotein E Gene Polymorphisms Are Strong Predictors of Inflammation and Dyslipidemia in Rheumatoid Arthritis , 2012, The Journal of Rheumatology.

[34]  L. Skov,et al.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study , 2011, Journal of Internal Medicine.

[35]  G. Kitas,et al.  Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. , 2008, Rheumatology.

[36]  J. Sieper,et al.  Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. , 2008, Arthritis and rheumatism.

[37]  T. Pincus,et al.  Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. , 2008, Atherosclerosis.

[38]  W. Ollier,et al.  HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[39]  T. Wadden,et al.  Tumor Necrosis Factor-α in Sera of Obese Patients: Fall with Weight Loss , 1998 .

[40]  E. Kalinina,et al.  COMORBIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS , 2019 .

[41]  Римма Михайловна Балабанова.  Анкилозирующий спондилит и коморбидность: безопасность длительного применения нимесулида , 2017 .

[42]  M. Z. Kanevskaya,et al.  [Comorbidity in rheumatoid arthritis: A focus on cardiovascular diseases]. , 2016, Klinicheskaia meditsina.

[43]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.